The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

Just days after getting FDA approval for Fabhalta as the first oral therapy for paroxysmal nocturnal haemoglobinuria (PNH), Novartis has reported new data showing it is also effective in C3 ...

Enter Novartis, with Fabhalta® (iptacopan), recently approved in the US and garnering early interest for use in later lines of therapy. Vanrafia®, also from Novartis, has just received its first ...

Hello, everyone. And welcome to the Q1 2025 Apellis Pharmaceuticals, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the presentation, there will be ...